FDA Investigator Wei Wang, PhD
Wei Wang, PhD has conducted inspections on 12 sites in 2 countries as of 21 Aug 2023. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
12
Last Inspection Date:
21 Aug 2023
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America,
United Kingdom of Great Britain and Northern Ireland
FDA Investigators that have inspected at least one site in common with Wei Wang, PhD:
Alberto A Viciedo,
Alla Kachko, PhD,
Anastasia I Offordile,
Andrew Byrnes, PhD,
Angela S Whatley,
Anissa M Cheung,
Anita R Michael,
Ann L Demarco,
Ann Marie Montemurro,
Ann Marie Schofield,
Anna R Kwilas,
Annet R Rajan,
Arie C Menachem,
Audrey Thereset Uy,
Barbara M Frazier,
Bo Liang, PhD,
Bradley Dworak, PhD,
Brentley S Collins,
Brian S Keefer,
Burnell M Henry,
Carl A Perez,
CDR Donald Ertel,
CDR Jeremy L Wally, PhD,
Chao Ming Tsai,
Christian D Lynch (CDL),
Christina J Sauder, PhD,
Christine A Harman, PhD,
Christopher J Adams,
Craig D Zagata,
Cynthia Jim, CSO,
Daniel C Kearns,
Dave Hafner,
David J Hafner,
Deborah M Trout,
Debra J Bennett,
Debra L Pagano,
Destry M Sillivan,
Devaughn Edwards,
Dino A Fiegelstock,
Donna D Gallien, MPH,
Douglas C Kovacs,
Dr. Gang Wang, PhD,
Dr. Willie F Vann, PhD,
Edmund F Mrak, Jr,
Eileen A Liu,
Eliezar Ramos,
Ellen Huang,
Eric J Cunningham,
Frank J Marciniak,
Gene D Arcy,
Graeme E Price,
Graeme Price,
Hala L Selby,
Haruhiko Murata,
Helen B Ricalde,
Hoda N Abadeer,
J David Doleski,
Jacqueline Mdiaz Albertini,
Jakob Reiser, PhD,
James E Keller, PhD,
James M Mason,
James R Evans,
Jennifer L Schmidt,
Jessica Chery,
Jessica S Estriplet,
Jianyang Wang,
Joan A Loreng,
Joan Adamo,
Joanne M Hajoway,
Jogy George,
Jose M Cayuela,
Joseph George,
Julianne C Mccullough,
Julie D Bringger,
Junho Pak,
Justin A Boyd,
Karen E D'orazio,
Karyn M Campbell,
Kathleen B Mihalik,
Kathryn Carbone, MD,
Kelly N Kerr,
Kenneth M Gordon,
Kinh Q Mac,
Kristen D Evans,
Kula N Jha,
Laressa R Gray,
Laurel A Beer,
Lauren M Lilly, PhD,
Laurie P Norwood,
LCDR Margaret Edi Gennaro,
Lewis K Antwi,
Li Li,
Linda Thai,
Lisa M Bellows,
Lisa M Feola,
LT John M Mastalski,
Marian E Major, PhD,
Marion Michaelis,
Mariza M Jafary,
Melanie L Drayton,
Melba Trivera Clavell,
Melissa A Zuppe,
Michael Curbarg,
Michael Gurbarg,
Michael Havert, PhD,
Michael R Klapal,
Michele L Forster, PhD,
Mihaly S Ligmond,
Nicole K Trudel,
Nikisha M Bolden,
Nikki S Ramirez,
Nirjal Bhattarai,
Omotunde O Osunsanmi,
Paige R Mccoy,
Pankaj K Mandal,
Paula A Trost,
Phillip C Thai,
Prabhu P Raju,
Prajakta A Varadkar,
Pratik S Upadhyay, DDC,
Priscilla M Pastrana,
Rabia Ballica, PhD,
Ralph A Erickson,
Ramon E Martinez,
Rebecca K Olin,
Richard Heath Coats,
Richard W Thornton,
Robert B Shibuya, MD,
Robert C Coleman,
Robert D Tollefsen,
Robert G Ruff,
Robert Jennings,
Robert Sausville,
Rose Ashley,
Sarah B Tanksley,
Scott E Norris,
Scott T Ballard,
Sheila Dreher Lesnick,
Sherry G Bous,
Shuang Tang,
Sidney B Priesmeyer,
Simone E Pitts,
Solomon Yimam (SY),
Stephanie Mangigian, MS/OSH, RN,
Stephen D Brown,
Stephenie M Ortiz,
Steven A Rubin,
Steven E Bowen, PhD,
Susan F Laska, MS,
Susan M Jackson,
Tammy L Chavis,
Thomas J Arista,
Tina S Roecklein,
Vlada Matusovsky,
Xiao Wang,
Xiuju Lu,
Yonggang Wang, PhD,
Yvesna C Blaise,
Zakaria I Ganiyu,
Zhaohui Ye
Wei Wang, PhD's Documents
| Publish Date | Document Type | Title |
|---|---|---|
| June, 2017 | FDA 483 | SAFC Carlsbad Inc. - Form 483, 2017-06-22 |
| February, 2019 | FDA 483 Response | Novartis Gene Therapies, Inc. - Form 483R, 2019-03-12 |
| June, 2017 | FDA 483 | KITE PHARMA, INC. - Form 483, 2017-06-16 |
| February, 2018 | FDA 483 | Symbiosis Pharmaceutical Services Limited - Form 483, 2018-02-23 |
| November, 2022 | FDA 483 | Krystal Biotech, Inc. - Form 483, 2022-11-16 |
| June, 2017 | EIR | KITE PHARMA, INC. - EIR, 2017-10-18 |
| February, 2019 | FDA 483 | Novartis Gene Therapies, Inc. - Form 483, 2019-02-08 |
| June, 2017 | FDA 483 Response | KITE PHARMA, INC. - Form 483R, 2017-06-29 |
| May, 2014 | FDA 483 | Sanofi Pasteur Inc. - Form 483, 2014-05-09 |
| February, 2013 | FDA 483 | Merck Sharp & Dohme LLC - Form 483, 2013-02-06 |
| May, 2014 | EIR | Sanofi Pasteur Inc. - EIR, 2014-05-09 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more